Nektar Therapeutics (NKTR)
NKTR Stock Price Chart
Explore Nektar Therapeutics interactive price chart. Choose custom timeframes to analyze NKTR price movements and trends.
NKTR Company Profile
Discover essential business fundamentals and corporate details for Nektar Therapeutics (NKTR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 May 1994
Employees
61.00
Website
https://www.nektar.comCEO
Howard W. Robin
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR Financial Timeline
Browse a chronological timeline of Nektar Therapeutics corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$2.96, while revenue estimate is $10.19M.
Earnings released on 7 Aug 2025
EPS came in at -$2.95 surpassing the estimated -$3.13 by +5.75%, while revenue for the quarter reached $11.18M , beating expectations by +18.68%.
Stock split effective on 9 Jun 2025
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2025
EPS came in at -$3.30 falling short of the estimated -$2.70 by -22.22%, while revenue for the quarter reached $10.46M , missing expectations by -31.88%.
Earnings released on 12 Mar 2025
EPS came in at -$2.25 falling short of the estimated -$1.95 by -15.38%, while revenue for the quarter reached $29.18M , missing expectations by -20.41%.
Earnings released on 7 Nov 2024
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%, while revenue for the quarter reached $24.12M , missing expectations by -23.15%.
Earnings released on 8 Aug 2024
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $23.49M , beating expectations by +33.92%.
Earnings released on 9 May 2024
EPS came in at -$0.18 surpassing the estimated -$0.21 by +14.29%, while revenue for the quarter reached $21.64M , beating expectations by +41.06%.
Earnings released on 4 Mar 2024
EPS came in at -$0.22 falling short of the estimated -$0.20 by -10.00%, while revenue for the quarter reached $23.89M , beating expectations by +32.33%.
Earnings released on 7 Nov 2023
EPS came in at -$0.19 falling short of the estimated -$0.18 by -5.56%, while revenue for the quarter reached $24.14M , beating expectations by +29.67%.
Earnings released on 8 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%, while revenue for the quarter reached $20.50M , missing expectations by -5.92%.
Earnings released on 9 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.26 by +3.85%, while revenue for the quarter reached $21.59M , beating expectations by +4.93%.
Earnings released on 28 Feb 2023
EPS came in at -$0.32 surpassing the estimated -$0.45 by +28.89%, while revenue for the quarter reached $22.02M , missing expectations by -0.51%.
Earnings released on 3 Nov 2022
EPS came in at -$0.24 surpassing the estimated -$0.47 by +48.94%, while revenue for the quarter reached $23.63M , beating expectations by +4.50%.
Earnings released on 4 Aug 2022
EPS came in at -$0.85 surpassing the estimated -$1.01 by +15.84%, while revenue for the quarter reached $21.59M , missing expectations by -4.56%.
Earnings released on 5 May 2022
EPS came in at -$0.49 surpassing the estimated -$0.72 by +31.94%, while revenue for the quarter reached $24.82M , beating expectations by +2.16%.
Earnings released on 28 Feb 2022
EPS came in at -$0.79 surpassing the estimated -$0.81 by +2.47%, while revenue for the quarter reached $25.01M , missing expectations by -27.01%.
Earnings released on 4 Nov 2021
EPS came in at -$0.70 surpassing the estimated -$0.80 by +12.50%, while revenue for the quarter reached $24.92M , missing expectations by -10.42%.
Earnings released on 5 Aug 2021
EPS came in at -$0.69 surpassing the estimated -$0.72 by +4.17%, while revenue for the quarter reached $28.33M , beating expectations by +9.05%.
Earnings released on 6 May 2021
EPS came in at -$0.68 surpassing the estimated -$0.72 by +5.56%, while revenue for the quarter reached $23.65M , missing expectations by -13.03%.
Earnings released on 25 Feb 2021
EPS came in at -$0.65 surpassing the estimated -$0.72 by +9.72%, while revenue for the quarter reached $23.46M , missing expectations by -30.13%.
Earnings released on 5 Nov 2020
EPS came in at -$0.61 surpassing the estimated -$0.80 by +23.75%, while revenue for the quarter reached $30.03M , missing expectations by -17.57%.
NKTR Stock Performance
Access detailed NKTR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.